Erratum

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women

W Jonat*

British Journal of Cancer (2002) 87, 1480. doi:10.1038/sj.bjc.6600652 www.bjcancer.com

© 2002 Cancer Research UK

Correction to: British Journal of Cancer 2001; 85 (Suppl 2): 1–5

An error has been noted within Figure 1. The chemotherapy regimen shown in the ECOG/SWOG/CALGB INT-0101 study is

incorrect and should be six cycles of CAF (cyclophosphamide/adriamycin/5-fluorouracil) and not six cycles of CMF (cyclophosphamide/methotrexate/5-fluorouracil), as presented. The corrected version of the figure is shown here.

Figure 1 Clinical trials designs for studies involved in the evaluation of goserelin as adjuvant treatment in early breast cancer in pre-/perimenopausal patients.

*Correspondence: Professor W Jonat, Department of Obstetrics and Gynecology, University of Kiel, Michaelisstrasse 16, D-241405 Kiel, Germany; E-mail: jonat@email.uni-kiel.de